Loading clinical trials...
Loading clinical trials...
This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Tenet Medicines
NCT05668403 · Primary Membranous Nephropathy
NCT07157787 · Primary Membranous Nephropathy
NCT07516964 · Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, and more
NCT04456816 · Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy
NCT03949855 · Membranous Nephropathy, Nephrotic Syndrome
Clinical Reserach Site
Los Angeles, California
Clinical Research Site
Albany, New York
Clinical Research Site
Bethlehem, Pennsylvania
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions